Regulatory Shift Sends Shockwaves Through Pfizer’s Investment Landscape
Published on 11/30/2025 at 06:03 | Redaktion boerse-global.de
Pfizer shareholders faced a tense weekend as conflicting signals emerged about the pharmaceutical giant’s future prospects. While some institutional investors are capitalizing on currently depressed share prices to increase their holdings, an aggressive stance from the U.S. Food and Drug Administration has created significant uncertainty. The regulatory body’s surprising criticism of previous approval processes has left market participants questioning whether the company faces a difficult regulatory battle or whether current panic presents a unique buying opportunity.
Amid the regulatory concerns, a glimmer of optimism emerged from Guggenheim analysts just before the weekend. The research firm raised its price target to $35 per share while maintaining a buy recommendation. This Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
